Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase III Study Of Low-Docetaxel Oxaliplatin, Capecitabine (Low-Tox) Vs Epirubicin, Oxaliplatin And Capecitabine (Eox) In Patients With Locally Advanced Unresectable Or Metastatic Gastric Cancer

NCT02076594 is registered in ClinicalTrials.gov with Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente as lead sponsor.

NCT NCT02076594
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02076594 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase III Study Of Low-Docetaxel Oxaliplatin, Capecitabine (Low-Tox) Vs Epirubicin, Oxaliplatin And Capecitabine (Eox) In Patients With Locally Advanced Unresectable Or Metastatic Gastric Cancer
Lead sponsor
Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente
Phase
Phase 3
Overall status
Terminated
Start date
January 31, 2013
Completion date
December 31, 2018
Enrollment
171 (actual)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced unresectable gastric cancer, metastatic gastric cancer